Testing medicines that calm the immune system in kids with Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 18 years old.
- A doctor has diagnosed you with Crohn’s disease.
- Your Crohn’s is considered “active,” based on either PCDAI (above 30) or an endoscopy score called SES-CD (above 10) before starting study treatment.
- You have already tried first-line treatment: either exclusive enteral nutrition (special formula feeding) or corticosteroids (steroids). After that, your scores must still show disease activity (PCDAI above 10 or SES-CD 3 or higher).
- You (or your legal guardian) can sign informed consent to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
Hear when a new Infliximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.